.
MergerLinks Header Logo

Announced

Completed

Impilo-backed Scantox completed the acquisition of the neuropharmacology division of QPS Austria.

Financials

Edit Data
Transaction Value-
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Friendly

Acquisition

Cross Border

Majority

Single Bidder

Private

Austria

Neuropharmacology

Biotechnology

Private Equity

Completed

Synopsis

Edit

Impilo-backed Scantox, a preclinical research company, completed the acquisition of the neuropharmacology division of QPS Austria, a full-service contract research organization. Financial terms were not disclosed. "The acquisition of QPS Neuro is meaningfully changing our lead optimization platform and expands the depth and breadth of our discovery services in the CNS and rare disease area. We see a strong fit with the Scantox organization and are deeply impressed with the dedicated management team, its staff and R&D efforts focused on providing an enhanced level of service and scientific excellence to their clients," Jeanet Løgsted, Scantox CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US